Anne worked for more than 30 years in the chemical industry holding various positions like Business Line Head (P&L), Global Key Account Manager and Head of Sales for various markets like pharma, medical devices, consumer care and crop protection. Anne started in 2018 as CBO at INOFEA and moved into the role as CEO in March 2019.

Rita started at INOFEA in 2017, first as Head of R&D and she is now responsible as CTO for R&D, Production and QA and as Group Leader for biocatalysis in small molecule API manufacturing. She developed INOFEA’s technology at FHNW as postdoc and graduated with a PhD in Biology focusing on Biochemistry at ETH Zurich.

Agnese earned her Bachelor of Science in Biological Sciences and her Master of Science in Molecular and Industrial Biotechnologies from the University of Naples "Federico II". She completed an internship at the Centre for Protein Engineering of the University of Liège, where she studied protein-RNA interactions. Agnese then earned her PhD in RNA Biology from the University of Zurich where she studied RNA processing enzymes. She has joined INOFEA as R&D Group Leader for mRNA IVT (In Vitro Transcription). Agnese is an expert in molecular biology enzymes and is passionate about the field of IVT. Her expertise significantly contributes to the company's strategic focus on Biologics. Agnese has developed valuable leadership skills, making her a strong asset in driving INOFEA's ambitious goals.

Aaron completed his master’s degree in interdisciplinary sciences, followed by a PhD thesis on protein engineering at ETH Zürich. During his tenure at Novartis as a postdoc, he focused on enzymatic peptide modification and bioconjugation. At INOFEA, he contributes his expertise as an R&D group leader in bioconjugation to further advance INOFEA‘s vision of enzymatically produced bioconjugates.

Marie earned a master’s degree in molecular and supramolecular chemistry from the University of Strasbourg along with an engineering degree from the ECPM (European School of Chemistry, Polymers and Materials Science). She worked as a research associate at NovAlix before starting her PhD at the University of Strasbourg. During her PhD, she focused on the development of red/NIR emitting dyes and their bioconjugation to nanobodies. During her postdoc at ICMUB (Institute of Molecular Chemistry from the University of Burgundy), she was responsible for R&D bioconjugation studies for industrial partners. At INOFEA, she contributes to enzymatic bioconjugation and biocatalysis.

Tina earned a master’s degree in Biotechnology and Pharmaceutical R&D from the University of Rijeka, followed by a PhD in Biochemistry and Molecular Biology from Université Grenoble Alpes, working at the prestigious European Molecular Biology Laboratory (EMBL). During her PhD, she investigated the correlation between RNA structure and function. During her postdoc as a Marie Curie Postdoctoral Fellow, she explored RNA function in humans by applying CRISPR technology. Tina joined INOFEA as Scientist for Enzymatic RNA In Vitro Transcription (IVT) and Downstream Purification, bringing her expertise in RNA biology to apply INOFEA’s technology to sustainable mRNA manufacturing.